Completed PHASE4 INTERVENTIONAL 3-arm NCT04238208

The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Males With Diabetic Neuropathy

The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients

Sponsor: Corporacion Parc Tauli

Conditions Diabetic Complications Neurological Diabetic Nerve Problems Diabetic Neuropathy

Interventions Capsaicin 8% Patch, Per 10 Square Centimeters Lidocaine 5% patch

Updated 4 times since 2020 Last updated: Jan 28, 2020 Started: Jan 10, 2019 Primary completion: Dec 10, 2019 Completion: Jan 2, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetic Complications Neurological and Diabetic Nerve Problems and is currently completed. Corporacion Parc Tauli leads this study, which shows 4 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Feb 2020 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Corporacion Parc Tauli

Data source: Corporacion Parc Tauli

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lahore, Pakistan